Drugs / CD34-TK75 transduced donor lymphocytes
CD34-TK75 transduced donor lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00871702 | Oct 2010 → Nov 2012 | Hodgkins lymphoma, leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34-TK75 transduced donor lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00871702 ↗ |
| Modality | Cell therapy | “Infusion of Genetically Modified T Cells” NCT00871702 ↗ |
| Route | Intravenous | “after intravenous infusion of the genetically modified cells (lymphocytes) into the recipient” NCT00871702 ↗ |